Specialities

Specialities

Respiratory Infections
Airway Diseases
Allergy
Asthma
Bronchiectasis
Bronchitis
Chronic Cough
COPD
COVID-19
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Interventional Pulmonology
Lung Cancer
Paediatric Respiratory Medicine
Respiratory Tract Disorders
Pulmonary Embolism
Pulmonary Hypertension
Respiratory Intensive Care
Rhinosinusitis
Sleep Related Breathing Disorders
Lung Transplantation and Surgery
Ventilation
Lung Health
Rare Diseases
Search

Trending Topic
14 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The Impact of Smart Inhalers on Personalized Asthma Management

Kate Clair Cruden Hughes, Amy Hai Yan Chan

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted to significantly impact asthma and other respiratory-related conditions, as rising global temperatures lead to longer pollen […]

touchREVIEWS in Respiratory & Pulmonary Diseases. 2025;10(1):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
Asthma

Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 15th 2021

It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma.

Questions

  1. How can we further personalise treatment for people with severe asthma? (0:11)
  2. What are the hot topics and latest research you are looking forward to exploring in severe asthma during 2021? (1:10)

Disclosures: Andrew Menzies-Gow discloses attending advisory boards for Astra Zeneca, Sanofi, Novartis and Glaxo SmithKline; Receiving speaker fees from AZ, Novartis, Teva and Sanofi; and has participated in research with AZ.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of ERS 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Is AI the future of decision-making in asthma diagnosis and treatment?

Alan Kaplan

Artificial intelligence is no longer a futuristic concept in respiratory care — it's already here, reshaping how we diagnose and manage asthma. In this insightful interview, Dr Alan Kaplan shares how AI is helping bridge long-standing gaps in asthma diagnosis, adherence, and disease control. From apps that can tell the difference between asthma and COPD, to smart inhalers that track medication use and predict exacerbations, Dr Kaplan explores the real-world potential of AI — and the challenges that come with it. He also weighs in on whether AI scribe software can enhance the patient–physician relationship, and what excites him most about the road ahead.

Advertisement

    • Related Videos in Asthma

    Latest articles videos and clinical updates - straight to your inbox

    Close Popup